Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 10/31/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: September 1, 2018 - September 30, 2018

 

MOR - 1

Consolidated Schedule of Cash Receipts and Disbursements (1)

For the Period: September 1, 2018 - September 30, 2018

(Unaudited)

 

$ USD ‘000s

  September 1, 2018 - September 30, 2018     Cumulative
Since Filing
 

Beginning Cash Balance (Book)

  $ 37,432     $ 21,372  

Receipts

   

Operating Receipts(2)

    (338     64,084  

Miscellaneous Receipts

    56       70,605  
 

 

 

   

 

 

 

Total Receipts

    (281     134,690  

Operating Disbursements

   

Payroll & Benefits / Contractors

    (644     (16,840

Inventory

    (3     (4,409

Manufacturing and Logistics

    (71     (204

Gross to Net Disbursements

    —         (36,451

Marketing / Commercial Operations

    (231     (16,229

Ordinary Course Professionals

    (286     (924

Rent / Facilities / Equipment

    (4     (564

Insurance

    (85     (364

IT / Utilities

    (30     (371

Regulatory and Compliance

    (72     (634

Other G&A

    (157     (1,085
 

 

 

   

 

 

 

Total Operating Disbursements

    (1,584     (78,076

Operating Cash Flow

    (1,866     56,614  

Reorganization Costs

   

DIP Loan Interest and Fees

    —         (44,480

US Trustee Fees

    —         (371

Restructuring Professional Fees

    (1,962     (5,525
 

 

 

   

 

 

 

Total Reorganization Costs

    (1,962     (50,376

Total Disbursements

  $ (3,546   $ (128,452
 

 

 

   

 

 

 

Lender Professional Fees

    (148     (1,753

Net Cash Flow

  $ (3,975   $ 4,485  

DIP Draw - Cash

    —         7,600  
 

 

 

   

 

 

 

Ending Cash Balance (Book)

  $ 33,457     $ 33,457  

Notes:

 

(1)

The Schedule of Cash Receipts and Disbursements is presented on a book basis.

(2)

The negative Operating Receipts in September relates to the reimbursement of operating receipts to the purchaser in connection with the Order Approving Stipulation Allocating Certain Closing Date Funds (Docket #0736). The full amount of closing date operating funds were recorded and disclosed in the July MOR.